Short answer
MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) filed its Q1 2026 10-Q quarterly report on May 8, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $66M (up 40.5% year over year) with net income of −$4M.
Q1 2026 key financials · XBRL
- Revenue
- $66M
- +40.5% YoY
- Net income
- −$4M
- +87.5% YoY
- Operating margin
- -3.3%
- Gross margin
- 51.2%
- EPS (diluted)
- −$0.02
- +90.5% YoY
Source: XBRL data from the MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) Q1 2026 10-Q on SEC EDGAR. USD.
MARAVAI LIFESCIENCES HOLDINGS, INC. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $65.8M, up $18.9M YoY from $46.9M
- TriLink revenue $47.5M vs $28.8M; Cygnus $18.4M vs $18.1M YoY
- CleanCap revenue $14.3M; no further high-volume COVID-19 orders expected in 2026
- SG&A $29.1M vs $39.6M; R&D $3.9M vs $4.9M YoY
- $50.0M Term Loan prepayment using cash on hand; Q1 expected to be 2026’s highest-revenue quarter
Risk Factors
- No material changes to risk factors disclosed in the December 31, 2025 Form 10-K
- No newly added risk factor identified for the quarter
- No material regulatory, legal, or compliance risk updates disclosed
- Executive insider trading plan covering up to 50,000 Class A shares through August 10, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other MARAVAI LIFESCIENCES HOLDINGS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.